Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy
Atsushi Yamaguchi, Yoshitaka Saito, Katsuya Narumi, et al.
Journal of Cancer Research and Clinical Oncology (2022) Vol. 149, Iss. 4, pp. 1659-1666
Closed Access | Times Cited: 11

Showing 11 citing articles:

The role of PD-1 signaling in health and immune-related diseases
Ruyue Chen, Yun Zhu, Yunyan Shen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 58
Multi-organ immune-related adverse events from immune checkpoint inhibitors and their downstream implications: a retrospective multicohort study
Guihong Wan, Wenxin Chen, Sara Khattab, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 8, pp. 1053-1069
Closed Access | Times Cited: 17
Oral and cutaneous immune‐related adverse events in cancer patients: Prevalence and overall survival
Osias Vieira de Oliveira Filho, Ivana Lameiras Gibbons, Yuri de Lima Medeiros, et al.
Oral Diseases (2024)
Closed Access | Times Cited: 5
Significantly Delayed Development of Polyarthritis with Active Tenosynovitis after Possible Temporary Neutropenic Immune-Related Adverse Events Caused by Atezolizumab Treatment: A Novel Case Report
Yoshitaka Saito, Yoh Takekuma, Hajime Asahina, et al.
Case Reports in Oncological Medicine (2024) Vol. 2024, pp. 1-5
Open Access | Times Cited: 2
Risk factors and outcomes of pericardial effusion in cancer patients receiving PD-1 inhibitors
Manyun Tang, Peizhu Dang, Tong Liu, et al.
International Journal of Cardiology (2024) Vol. 407, pp. 132029-132029
Open Access | Times Cited: 2
Immune-related adverse events correlate with the clinical efficacy in advanced Non-Small-Cell Lung Cancer patients treated with PD-1 inhibitors combination therapy
Xiaohong Xie, Yuhao Li, Qiaomei Lv, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Experience of Chinese oncology nurses in providing care for patients with cutaneous toxicity of immunotherapy: A qualitative study
Zhihui Yang, Suting Liu, Xingwen Li, et al.
Research Square (Research Square) (2024)
Open Access
Single-cell RNA sequencing analysis of peripheral blood mononuclear cells in PD-1-induced renal toxicity in patients with lung cancer
Shusu Liu, Peiyu Lu, Bixia Yang, et al.
BMC Nephrology (2024) Vol. 25, Iss. 1
Open Access
The impact of immune-related adverse events on the outcome of advanced gastric cancer patients with immune checkpoint inhibitor treatment
Tianhang Zhang, Haitao Lv, J. Li, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Associations Between Cutaneous and Noncutaneous Adverse Events Among Patients on Immune Checkpoint Inhibitors
Anna Eversman, Christopher J Thang, David Gárate, et al.
Journal of the American Academy of Dermatology (2024)
Closed Access
Association Between Multisystem Immune-related Adverse Events and Progression-free Survivals in PD-1/PD-L1 Inhibitor Monotherapy
Atsushi Yamaguchi, Yoshitaka Saito, Keisuke Okamoto, et al.
In Vivo (2024) Vol. 38, Iss. 6, pp. 2886-2896
Open Access
Page 1

Scroll to top